Replimune Investors Urged to Act Over 73% Stock Drop Amid FDA Biologics License Application Issue
A leading national securities law firm is investigating potential claims against Replimune Group, Inc. following a significant stock drop after the company received a Complete Response Letter from the FDA regarding its Biologics License Application for advanced melanoma treatment. Replimune’s stock plummeted over 73% on July 22, 2025, amid concerns over the FDA’s decision to … Read more